Stockscreener 앱 받기
1.16
7.41%
0.08
시간 외 거래:
1.15
-0.01
-0.86%
전일 마감가:
$1.08
열려 있는:
$1.1
하루 거래량:
289.21K
Relative Volume:
1.40
시가총액:
$147.62M
수익:
-
순이익/손실:
$-18.43M
주가수익비율:
-7.4454
EPS:
-0.1558
순현금흐름:
$-12.87M
1주 성능:
+2.65%
1개월 성능:
-14.07%
6개월 성능:
-19.44%
1년 성능:
-27.50%
1일 변동 폭
$1.06
$1.16
1주일 범위
$1.04
$1.1694
52주 변동 폭
$1.04
$2.60
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Compare TLSA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.16 | 147.62M | 0 | -18.43M | -12.87M | -0.1558 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-22 | 개시 | B. Riley Securities | Buy |
| 2018-12-17 | 개시 | Laidlaw | Buy |
Tiziana Life Sciences Ltd 주식(TLSA)의 최신 뉴스
Tiziana Life Sciences Ltd (TLSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tiziana Life Sciences Ltd (TLSA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tiziana Life Sciences Ltd (TLSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Why Tiziana Life Sciences Is Back on the Small-Cap Radar? - Kalkine Media
Tiziana Life Sciences Ltd (TLSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tiziana Life Sciences Ltd (TLSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tiziana Life Sciences Ltd (TLSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tiziana Life Sciences Ltd (TLSA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tiziana Life Sciences Ltd (TLSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tiziana Life Sciences Ltd (TLSA) Institutional Confidence - TradingKey
Tiziana Life Sciences (TLSA) insider awarded 15,000 common shares - Stock Titan
Tiziana Life Sciences Ltd announced that it has received $0.01665 million in funding - marketscreener.com
Tiziana Life Sciences (TLSA) Executive Chairman Boosts Stake wit - GuruFocus
Tiziana Life Sciences (TLSA) Executive Chairman Boosts Shareholding - GuruFocus
Tiziana executive chairman increases stake - Proactive financial news
Tiziana Life Sciences Chair Boosts Stake as Foralumab Trials Advance - TipRanks
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman - The Manila Times
Tiziana (NASDAQ: TLSA) chair lifts stake with 15,000-share purchase - Stock Titan
Founder now owns 34.89% of Tiziana Life Sciences after 15K-share buy - Stock Titan
Tiziana Life Sciences (TLSA) Retreats 2.6% as Shares Approach Key SupportGolden Cross - newsline.com
[6-K] Tiziana Life Sciences Ltd Current Report (Foreign Issuer) | TLSA SEC FilingForm 6-K - Stock Titan
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York - NTB Kommunikasjon
Tiziana Life Sciences to present clinical updates at Jefferies healthcare conference - Proactive financial news
Biotech Tiziana to brief investors on clinical updates at Jefferies event - Stock Titan
Tiziana Life Sciences (TLSA) Slips 2.65% as Stock Tests Key Support ZoneVolume Oscillator - The Legal Advocate
Tiziana Life Sciences (TLSA) COO discloses Form 3 share and option holdings - Stock Titan
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI - Yahoo! Finance Canada
Tiziana Life Sciences completes enrollment in Phase 2a trial for multiple sclerosis drug foralumab - Pluang
Tiziana Life Sciences (TLSA) Completes Patient Enrollment in Cli - GuruFocus
Tiziana completes enrollment for Phase 2 trial in progressive MS study - Proactive financial news
Why Is TLSA Stock Rising Today? - Stocktwits
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial - Yahoo! Finance Canada
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial - The Manila Times
Phase 2a MS trial fully enrolled at Tiziana Life Sciences (NASDAQ: TLSA) - Stock Titan
Tiziana Life Sciences (TLSA) Drops 9% as Biotech Sector Volatility WeighsButterfly Setup - The Legal Advocate
Tiziana Life Sciences Shares Drop After Company Unveils Plan to Spin Out IL-6 Program - MSN
Tiziana Life Sciences (TLSA) Reports Positive Data on Foralumab for Multiple Sclerosis - GuruFocus
Updated Clinical Results for Tiziana Life Sciences (TLSA) Show P - GuruFocus
Tiziana Life Sciences price target boosted on foralumab update - Yahoo! Finance Canada
Market movers: Amer Sports, Tiziana Life Sciences, Ideal Power, NanoViricides... - Proactive financial news
Tiziana reports encouraging Expanded Access data for Foralumab in MS patients - Proactive financial news
Tiziana posts new data for multiple sclerosis drug (TLSA) - Seeking Alpha
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis - BioSpace
Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS - Yahoo! Finance Canada
Intranasal foralumab shows SPMS safety and fatigue gains at Tiziana (Nasdaq: TLSA) - Stock Titan
About Us - FinancialContent
Tiziana Brain Trial Draws Fresh Nasdaq Index Attention - Kalkine Media
Tiziana Life Sciences (TLSA) Reports Positive Early Results in C - GuruFocus
Small cap wrap: VivoPower, BioHarvest Sciences, Phunware, Tiziana Life Sciences… - Proactive financial news
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab - Investing News Network
Tiziana Life Sciences (TLSA) Reports Positive Early Results in Clinical Trial - GuruFocus
Tiziana Life Sciences Ltd (TLSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):